PBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Prestige Consumer Healthcare Inc (PBH) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is declining, analysts have lowered price targets, and there are no significant positive catalysts or signals from Intellectia Proprietary Trading Signals. The technical indicators are neutral, and options data does not show strong sentiment. Therefore, it is better to hold off on investing in PBH at this time.
The MACD histogram is positive at 0.439 and expanding, indicating slight bullish momentum. RSI is neutral at 53.267, and moving averages are converging, showing no clear trend. Key support is at $55.748, and resistance is at $58.857. Overall, the technical indicators suggest a neutral stance.
Hedge funds are significantly increasing their buying activity, with a 622.44% increase in the last quarter.
Insiders are selling heavily, with a 291.04% increase in selling activity over the last month. Financial performance in Q3 2026 shows declining revenue, net income, and EPS. Analysts have lowered price targets and expect shares to remain range-bound without a catalyst.
In Q3 2026, revenue dropped by -2.37% YoY to $283.4M, net income fell by -23.49% YoY to $46.7M, and EPS decreased by -20.49% YoY to $0.97. Gross margin slightly declined to 53.7%. Overall, the financial performance shows a downward trend.
Canaccord maintains a Buy rating but lowered the price target from $88 to $86, citing a slight miss in sales due to supply issues. Jefferies maintains a Hold rating and reduced the price target from $70 to $66, citing weak U.S. OTC trends and lack of a near-term catalyst.
